Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2 [Breast Cancer]

Conclusion
The data from this exploratory analysis suggest that the efficacy of everolimus was largely independent of the most commonly altered genes or pathways in hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer. The potential impact of chromosomal instabilities and low-frequency genetic alterations on everolimus efficacy warrants further investigation.

Source: Journal of Clinical Oncology - February 2, 2016 Category: Cancer & Oncology Authors: Hortobagyi, Chen, Piccart, Rugo, Burris, Pritchard, Campone, Noguchi, Perez, Deleu, Shtivelband, Masuda, Dakhil, Anderson, Robinson, He, Garg, McDonald, Bitter, Huang, Taran, Bachelot, Lebrun, Lebwohl, Baselga Tags: Combined Modality, Hormonal Therapy Breast Cancer Source Type: research